Interestingly, in this context, the use of ZIF-90 represents the possibility of delivering blockers or modulators of intermediate conductance calcium-activated potassium channels (KCa3.1) involved in human glioblastoma malignancy [57,58,59]. This evidence concerns the gene KCNN4 and glioblastoma.